Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  FibroGen Inc    FGEN

FIBROGEN INC (FGEN)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/11/2018 01/12/2018 01/16/2018 01/17/2018 01/18/2018 Date
48.95(c) 49.5(c) 47.8(c) 48.2(c) 47.675 Last
305 538 337 707 668 323 449 883 155 128 Volume
+1.98% +1.12% -3.43% +0.84% -1.09% Change
More quotes
Financials ($)
Sales 2017 133 M
EBIT 2017 -116 M
Net income 2017 -126 M
Finance 2017 759 M
Yield 2017 -
Sales 2018 258 M
EBIT 2018 -60,5 M
Net income 2018 -97,8 M
Finance 2018 317 B
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 24,1x
EV / Sales2018 -1 213x
Capitalization 3 962 M
More Financials
Company
FibroGen, Inc. operates as a science-based biopharmaceutical company, which engages in the discovery, development, and commercialization of therapeutics to treat unmet medical needs.It focuses on fibrosis and hypoxia-induced factor biology to generate programs targeting therapeutic areas.The... 
More about the company
Surperformance© ratings of FibroGen Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on FIBROGEN INC
01/08 FIBROGEN INC : Regulation FD Disclosure, Financial Statements and Exhibits (form..
01/04 FIBROGEN : Study Findings on Small Molecule Inhibitors Are Outlined in Reports f..
2017 FIBROGEN : reports 3Q loss
2017 FIBROGEN : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESUL..
2017 FIBROGEN INC : Results of Operations and Financial Condition, Financial Statemen..
2017 FibroGen Reports Third Quarter 2017 Financial Results
2017 FIBROGEN INC : FibroGen, Inc. to Host Earnings Call
2017 ASTELLAS PHARMA : and FibroGen Announce Positive Topline Results from First Japa..
2017 FIBROGEN INC : Other Events, Financial Statements and Exhibits (form 8-K)
2017 FIBROGEN : to Report Third Quarter Financial Results on Wednesday, November 8, 2..
More news
Sector news : Biotechnology & Medical Research - NEC
01/17 CELGENE : Conducts Deal Talks With Juno -- WSJ
01/16 CELGENE : in Talks to Buy Juno Therapeutics -- Update
01/16 CELGENE : in Talks to Buy Juno Therapeutics
01/12 Drugmakers see a pricing blueprint in an $850,000 gene therapy
01/12 SPARK'S PRICE FOR LUXTURNA BLINDNESS : Icer
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
08:01aFibroGen $FGEN Given Daily News Sentiment Rating of 0.21  
07:59a$FGEN - FibroGen #FGEN Given Daily News Sentiment Rating of 0.21  
01/17$FGEN just FYI - I am massively biased thinking big material upside for this .. 
01/17Want automatic email alerts for $FGEN $JD $STML $VCV $LAND? Subscribe to Mark.. 
01/16$CELG looking to buy $JUNO. IF so, $BLUE gaps to $200? $FGEN will be bo.. 
More tweets
Qtime:221
News from SeekingAlpha
01/10 YOUR DAILY PHARMA SCOOP : Aradigm Sees Sell-Off Ahead Of Ad Com, Editas Provides..
01/04 YOUR DAILY PHARMA SCOOP : Ardelyx Reports Data, Omeros Moves Forward With OMS721..
2017 YOUR DAILY PHARMA SCOOP : Synergy's New CEO, AbbVie Data, TiGenix Changes
2017 YOUR DAILY PHARMA SCOOP : Ultragenyx Sells Voucher, Regeneron Announces Collabor..
2017 YOUR DAILY PHARMA SCOOP : Conatus Looks Undervalued, Teva Announces Restructurin..
Chart FIBROGEN INC
Duration : Period :
FibroGen Inc Technical Analysis Chart | FGEN | US31572Q8087 | 4-Traders
Technical analysis trends FIBROGEN INC
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 69,0 $
Spread / Average Target 43%
EPS Revisions
Managers
NameTitle
Thomas Byron Neff Chairman & Chief Executive Officer
Pat Cotroneo Chief Financial Officer & Vice President-Finance
Kin Hung Yu Chief Medical Officer
Jorma Tapio Routti Independent Director
Kalevi Kurkijärvi Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
FIBROGEN INC0.84%3 929
CELLTRION, INC.--.--%40 725
IQVIA HOLDINGS INC2.07%20 784
LONZA GROUP2.47%20 682
INCYTE CORPORATION-3.23%19 342
ALNYLAM PHARMACEUTICALS, INC.-1.90%12 256